1. Introduction {#sec1}
===============

Type 2 diabetes is a chronic metabolic disorder characterized by hyperglycemia due to defects in insulin secretion, action, or both \[[@B1], [@B2]\]. In 2015, approximately 415 million people worldwide had diabetes, including 230 million Asians \[[@B3]\], and this is projected to increase to 642 million people worldwide and 355 million Asians by 2040. The rapidly growing incidence of diabetes is a serious problem \[[@B3]\]. Despite the high prevalence of diabetes in the general and elderly population, the appropriate glycemic goal remains controversial because large-scale longitudinal studies for diabetic complications, such as nephropathy, are lacking.

The widely accepted glycated hemoglobin (HbA~1c~) goal of \<53 mmol/mol (7.0%) is based on the results of the Diabetes Control and Complication Trial and UK Prospective Diabetes Study (UKPDS), which showed that HbA~1c~levels \< 53 mmol/mol (7.0%) reduced the risk of microvascular complications \[[@B4]--[@B6]\]. Based on these findings, many organizations, including the Korea Diabetes Association, recommend maintaining a target HbA~1c~ \< 48 mmol/mol (6.5%) for the general population with type 2 diabetes patients, and 53 mmol/mol (7.0%) for type 1 diabetes patients or elderly type 2 diabetes patients. However, although it was still effective in preventing the development and progression of nephropathy and albuminuria, intensive glycemic control failed to show a protective effect in reducing cardiovascular complications in elderly patients with longstanding diabetes or cardiovascular risks \[[@B7]--[@B9]\]. Furthermore, the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial revealed a higher mortality rate in the intensive glucose-lowering treatment group \[[@B9]\]. Subsequent observational studies have also revealed conflicting results regarding optimal glycemic targets \[[@B10]--[@B12]\].

Chronic kidney disease (CKD) is one of the major complications of diabetes. It occurs in approximately one-third of patients with diabetes \[[@B13]\]. In the Veterans Affairs Diabetes Trial (VADT) \[[@B14]\], intensive glycemic control did not significantly affect the progression of renal disease in the entire cohort except in the high-risk groups. However, a recent meta-analysis showed that intensive glucose control over 5 years reduced both kidney and eye events \[[@B15]\].

CKD and diabetes reinforce the risk of cardiovascular disease \[[@B16]\]; thus, given the increasing prevalence of diabetes and longstanding diabetes, the burden of CKD might increase in the future. Data for determining the appropriate HbA~1c~ level to prevent CKD in specific elderly patients with type 2 diabetes are limited. Thus, this study is aimed at investigating the association between target HbA~1c~ and the risk of CKD development and its progression in elderly patients with longstanding diabetes. Towards this goal, we conducted a large-scale analysis of a Korean Veterans Diabetes cohort.

2. Materials and Methods {#sec2}
========================

2.1. Subjects {#sec2.1}
-------------

This was a retrospective cohort study of patients with type 2 diabetes in the outpatient clinic of the Veterans Health Service Medical Center (Seoul, Korea). Since electronic medical records (EMR) were first introduced in this hospital in 2008, we screened patients who had been followed for at least 10 years and whose HbA~1c~ values were measured both in the first year (2008) and in the last year (2017) of the study. The inclusion criteria were as follows: (1) outpatients aged 18 years or older who visited the endocrinology department with type 2 diabetes (defined using the ICD-10 codes E11.0--11.9) in 2008 and (2) first HbA~1c~ ≥ 48 mmol/mol (6.5%) or at least taking antidiabetic medication. Further, most study subjects were regular patients at the outpatient clinic. At the beginning of the study, patients with ESRD were excluded, because they no longer showed a progression of renal complications or the development of ESRD, which are the primary endpoints of the current study. Of the 3648 patients identified, we excluded 549 patients with evidence of end-stage renal disease (ESRD) before the baseline period (*n* = 2), those who had missing data (serum creatinine and urine protein within 2 years of the initial and last year of the study period; *n* = 316), and those who had malignancies affecting diabetes progression (stomach, pancreas, and kidney; *n* = 231). Finally, 3099 patients were included. Available data of these patients were extracted from the Veterans Hospital Medical Information System (ezCaretech, Korea) using a clinical data warehouse. This study was approved by the Institutional Research Committee (IRB No. 2017-11-002), and the need for informed consent was waived owing to the retrospective study design.

### 2.1.1. HbA~1c~ Categories and Variables {#sec2.1.1}

Because the existing target HbA~1c~ levels have been suggested in 0.5% increments, the patients were divided into six groups according to their baseline or median dynamic HbA~1c~ levels as follows: \<48 mmol/mol (6.5%), 48--53 mmol/mol (6.5--7.0%), 53--58 mmol/mol (7.0--7.5%), 58--64 mmol/mol (7.5--8.0%), 64--69 mmol/mol (8.0--8.5%), and ≥69 mmol/mol (8.5%). Dynamic HbA~1c~ was defined as the HbA~1c~ values, measured at approximately two-year intervals during the follow-up period or until the events occurred. HbA~1c~ were measured by high-performance liquid chromatography (HLC-723G7; Tosoh, Tokyo, Japan) certified by the National Glycohemoglobin Standardization Program (NGSP). Baseline covariates were obtained within the first 2 years of study and included demographics, such as age and sex. Body mass index (BMI) was calculated as weight (kg) divided by height^2^ (kg/m^2^). Blood pressure was measured using an automatic manometer. Blood samples were obtained after at least 8 hours of fasting. High-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, uric acid, and creatinine were measured using an enzymatic colorimetric method (Toshiba Medical System Co. Ltd., Tokyo, Japan). As an indicator of renal complication, serum creatinine and urine protein levels were measured 1.9 times per year and 1.47 times per year on average, respectively, over the entire study period. The estimated glomerular filtration rate (eGFR) was calculated using the abbreviated Modification of Diet in Renal Disease equation as follows: 175 × serum creatinine^−1.154^ × age^−0.203^ (×0.742 if female) \[[@B17]\]. Baseline comorbidities and other diabetes complications were extracted from the electronic medical records throughout the study period defined by the following ICD-10 codes: hypertension (I10.9--11.0), hyperlipidemia (E78.0--78.5), ischemic heart disease (I20.0--24.9), heart failure (I50.0--51.9), cerebrovascular disease (I60.0--69.0), diabetic retinopathy associated with type 2 diabetes mellitus (E11.30--11.38), type 2 diabetes with neuropathy (E11.28--11.42), and diabetic foot (E11.7 and E14.8). Prescription data for statin, antihypertensive agents, and glucose-lowering agents were investigated, and the baseline medication was included if the drug was started within 3 years from the start of the study.

### 2.1.2. Assessment of Renal Complications {#sec2.1.2}

Renal complication was assessed using eGFR and albuminuria categories according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines \[[@B18]\]. CKD development and progression were also defined according to the KDIGO guidelines. CKD stage 1--2 with normal to mildly increased albuminuria was considered as a normal renal function (CKD-naïve during the initial study period). New CKD development was defined as having an eGFR \< 60 mL/min/1.73 m^2^ or albuminuria \> 3 mg/mmol over 3 months in CKD-naïve patients. CKD progression was defined as a decline in the eGFR category without reversion. Due to the variable amount of albuminuria, a decline in albuminuria category was considered as increased, but not interpreted as CKD progression. As defined, CKD progression was possible only in preexisting CKD patients (CKD stage 3A, 3B, 4, and/or albuminuria at moderately or severely increased levels). The time of CKD progression was calculated as the time at which the stage was deteriorated owing to a decreased eGFR in patients with CKD stage 3A, 3B, or 4 at the beginning of the study. ESRD development was defined as an eGFR \< 15 mL/min/1.73 m^2^. Based on initial values, subjects were divided into two groups as the CKD-naïve group and the preexisting CKD group, and changes in renal function were estimated. The proportion of patients who developed CKD in the CKD-naïve group and CKD progression in the preexisting CKD group was analyzed with the final eGFR and albuminuria category in the last observation at 10 years. In the survival analysis, the renal outcome was defined as a composite of CKD development in the CKD-naïve group and CKD progression in the preexisting CKD group. Because the group with normal GFR with micro-/macroalbuminuria was neither CKD naïve nor CKD, by definition, it was not included in the CKD analysis. In contrast, it was included in the ESRD analysis, which was performed in all subjects.

2.2. Data Analyses {#sec2.2}
------------------

The characteristics of the enrolled patients were analyzed based on the six baseline HbA~1c~ categories. Categorical data were analyzed using Fisher\'s exact or Chi-square tests. One-way analysis of variance was used for continuous variables, and Tukey\'s test was used as a post hoc test. Survival analysis was initiated from the day of first HbA~1c~ measurement in 2008 and ended the day of the last HbA~1c~ measurement in 2017, or the day when the events (e.g., renal or other complications) were first identified. Individuals without an event until the end of the follow-up were considered as censoring. Kaplan-Meier methods with log rank tests were used to estimate survivals of CKD and ESRD according to baseline or dynamic HbA~1c~ groups. An extended Cox model was used to identify risk factors of the events. We considered the dynamic HbA~1c~ value as a time-varying covariate. Statistically significant variables in the univariable Cox model were included in the multivariable Cox model. Variable selection was performed through a backward stepwise process until the smallest Akaike information criterion value had been reached. Hazard ratios (HRs) of the baseline and dynamic HbA~1c~ group were presented with 95% confidence intervals, after adjustment for age, sex, BMI, systolic blood pressure, HDL cholesterol, antihypertensive, glucose-lowering agents, baseline proteinuria, and eGFR. In addition, we performed a Cox regression with propensity scores as weights for the sex ratio for each HbA~1c~ group (baseline and dynamic). The proportional hazard assumption was evaluated using the Schoenfeld residuals method. When the proportional hazard assumption was violated, the time-dependent coefficient analysis was considered, and the hazard ratios were estimated separately in appropriate time intervals. Data analyses were performed by a statistical expert (Y.L.) using the R Statistical Package, Version 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria). Statistical significance was set at *p* \< 0.05.

3. Results {#sec3}
==========

3.1. Patient Characteristics according to Baseline HbA~1c~ {#sec3.1}
----------------------------------------------------------

The patients\' baseline characteristics are shown in [Table 1](#tab1){ref-type="table"}. The mean age was 64.67 ± 6.60 years, and 85.48% were men. The longitudinal data of median HbA~1c~ are presented every two years according to the HbA~1c~ category in Electronic Supplementary Figure [1](#supplementary-material-1){ref-type="supplementary-material"}. The HbA~1c~ curve maintained similar values in each group over time, except for the initial values at a higher HbA~1c~ ≥ 64 mmol/mol (8.0%), which shows a marked decrease afterwards.

### 3.1.1. Renal Complications {#sec3.1.1}

At the beginning of the study, 2357 (76.06%) patients were CKD-naïve and 412 (23.94%) patients had preexisting CKD ([Figure 1](#fig1){ref-type="fig"}). During the study period, 27.24% of the CKD-naïve patients developed new CKD; 50.24% of the preexisting CKD patients had CKD progression. In the groups with initial eGFR ≥ 60 mL/min/1.73 m^2^ with moderate to severe albuminuria, 42.42% of the patients progressed to declined eGFR. The group with initial eGFR \< 60 mL/min/1.73 m^2^ with/without albuminuria developed ESRD at the highest rate of 8.25%, while the overall incidence of ESRD was 1.7%.

### 3.1.2. Hazard Ratio of Glycemic Control for CKD and ESRD {#sec3.1.2}

Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"} present survival rates for the first progression of CKD or ESRD according to baseline HbA~1c~. The group with HbA~1c~ ≥ 64 mmol/mol (8.0%) had a higher progression rate for CKD (log rank *p* \< 0.001 for both baseline and dynamic HbA~1c~, [Figure 2](#fig2){ref-type="fig"}, and Supplementary Figure [2](#supplementary-material-1){ref-type="supplementary-material"}). For ESRD development, the group with HbA~1c~ ≥ 69 mmol/mol (8.5%) had a higher risk compared to the rest of the groups (log rank *p* = 0.025 for baseline HbA~1c~ in [Figure 3](#fig3){ref-type="fig"}, and log rank *p* = 0.003 for dynamic HbA~1c~ in the Supplementary Figure [3](#supplementary-material-1){ref-type="supplementary-material"}).

In the multiple Cox regression ([Table 2](#tab2){ref-type="table"}), baseline HbA1c showed high time-dependent hazard ratios for CKD from the second year of the study and ESRD for the entire follow-up period. Dynamic HbA~1c~ was also a risk factor for CKD with the satisfaction of proportional hazard assumption, but not for ESRD (Supplementary Table [1](#supplementary-material-1){ref-type="supplementary-material"}).

For the group with baseline HbA~1c~ ≥ 69 mmol/mol (8.5%), the hazard ratio was 1.98 (95% CI, 1.52--2.57) for CKD development or progression and 4.52 (95% CI, 1.44--14.13) for ESRD development ([Table 3](#tab3){ref-type="table"}). For dynamic HbA~1c~, there was an increased risk for CKD at ≥69 mmol/mol (8.5%, HR = 2.32; 95% CI, 1.76--3.05, Supplementary Table [2](#supplementary-material-1){ref-type="supplementary-material"}). The composite risk for CKD was marginally elevated in patients with baseline HbA~1c~ 64--69 mmol/mol (8.0--8.5%) even after weighted analysis ([Table 3](#tab3){ref-type="table"}, Supplementary Table [2-4](#supplementary-material-1){ref-type="supplementary-material"}). In contrast, there was no increased risk in those with baseline or dynamic HbA~1c~ of \<64 mmol/mol.

3.2. Other Microvascular Complications {#sec3.2}
--------------------------------------

Both baseline and dynamic HbA~1c~ were associated with neuropathy risk at 0-60 months, retinopathy risk after 60 (70 for dynamic) months, and risk for diabetic foot over the entire period ([Table 2](#tab2){ref-type="table"} and Supplementary Table [1](#supplementary-material-1){ref-type="supplementary-material"}). The HbA~1c~ group with ≥58 mmol/mol (7.5%) showed a higher risk for neuropathy (during 22--110 months) and retinopathy (after 60 months, [Table 3](#tab3){ref-type="table"} and Supplementary Table [2--4](#supplementary-material-1){ref-type="supplementary-material"}) before and after weighted analysis. Meanwhile, there was no increased risk for any complications at baseline or dynamic HbA~1c~ \< 58 mmol/mol (7.5%) for the entire period.

4. Discussion {#sec4}
=============

The current study showed the development and progression of renal complications in the Korean Veterans Diabetes Cohort, which is mostly composed of older men with type 2 diabetes. A higher HbA~1c~ ≥ 69 mmol/mol (8.5%) was associated with an increased risk of renal complications, while the risk for other complications was elevated at a HbA~1c~ of ≥58 mmol/mol (7.5%) with a time-varying effect. Based on our 10-year analysis, a slight upward adjustment of target HbA~1c~ below 58 mmol/mol (7.5%) can be acceptable in older patients to reduce the risk for renal and other complications for a decade or so.

This is somewhat higher than the usual HbA~1c~ target of 48--53 mmol/mol (6.5--7.0%). A meta-analysis of UKPDS, Action in Diabetes and Vascular Disease (ADVANCE), and ACCORD trials showed that intensive glycemic control (median HbA~1c~: 46--57 mmol/mol, 6.4--7.4%) reduced the risk for the development of CKD compared to that of a conventional control (median HbA~1c~: 56--79 mmol/mol, 7.3--9.4%) \[[@B19]\]. Many guidelines still recommend maintaining a target HbA~1c~\<48 mmol/mol (6.5%) or 53 mmol/mol (7.0%). Only a few guidelines suggested the targets for HbA~1c~ below 58 mmol/mol (7.5%), 64 mmol/mol (8.0%), or 69 mmol/mol (8.5%) in elderly type 2 diabetes patients.

In elderly patients, the correlation between glycemic control and renal outcomes tends to be more ambiguous with their comorbid condition as shown in a previous large-scale cohort study \[[@B20]\]. In a posttrial follow-up of the ADVANCE trial, the benefit of intensive glucose control on ESRD was only in the groups with no CKD or CKD stage 1--2, but not significant in the group with CKD stage 3 \[[@B21]\]. This is relevant to the current patients who were elderly veterans with several comorbidities. For elderly patients, it may be reasonable to suggest a slightly higher glycemic control target, because previous studies showed higher mortality at HbA~1c~ \< 42 mmol/mol (6.0%), with the relationship showing a U-shaped curve \[[@B10], [@B20], [@B22]--[@B26]\]. Some studies have suggested individualized strategies for diabetes treatment, especially in the elderly \[[@B27]\]. This is consistent with the purpose and the results of our study, suggesting a slightly higher target HbA~1c~ while minimizing the risk of long-term complications.

Renal outcomes are variably defined as a composite of deterioration in albuminuria and GFR decline, which may lead to discrepancies in the study results. In UKPDS, ACCORD, ADVANCE, and VADT, intensive glycemic control reduced the risk of albuminuria, but not the risk of GFR decline \[[@B4], [@B7]--[@B9], [@B14]\]. The lower risk in renal outcome at somewhat higher HbA~1c~ of ≥69 mmol/mol (8.5%) in this study might be because our definition of CKD included decreased eGFR, rather than only incident albuminuria according to the recent KDIGO guideline \[[@B18]\].

Blood pressure control, together with antihypertensive drugs, is effective in preventing CKD progression \[[@B28]--[@B30]\]. In our cohort, angiotensin blockers had already been administered in most patients with hypertension. Thus, the effect of hypertension is presumed to be diluted. Recent studies demonstrated that sodium-glucose cotransporter 2 or glucagon-like peptide-1 also have protective effects against CKD progression \[[@B31], [@B32]\]. Because these drugs were not introduced before 2017, they were not included in our study.

There are only a few studies on the progression of renal outcome in type 2 diabetes. Data from UKPKDS showed the prevalence of diabetic kidney disease of 28.6% and renal replacement therapy of 0.4% at 10 years \[[@B33]\], consistent with our findings. A recent study reported no difference in the type of diabetes, age, and sex in the progression of nephropathy \[[@B34]\]. Considering this, the findings from our cohort, which is comprised of mostly older men, may be applied to younger patients or women.

This study has some limitations. Because of the retrospective cohort design, there may be unmeasured confounding factors, and a causal relationship cannot be made. There were some missing data on smoking or diabetes duration, which are known to be important risk factors for renal outcomes \[[@B35]\]. Earlier studies, however, failed to find significant associations between renal complications and smoking \[[@B14], [@B36], [@B37]\] or diabetes duration \[[@B10]\]. Because the current study sample consists primarily of male veterans, results must be carefully interpreted when attempting to generalize the findings to the entire population, although our weighted analysis with the sex ratio showed similar results. In our study, neuropathy and retinopathy, as well as baseline comorbidities, were identified using the diagnostic code, and there may be a risk of overestimation or misclassification, and variations depending on the clinicians. In addition, there may be selection bias, because cases with missing data for HbA~1c~, eGFR, and proteinuria at the beginning and end of the study were excluded. However, a major strength of the present study is the large veteran cohort of elderly men with a long-term follow-up observation of 10 years and which features a low dropout rate. The natural history of diabetic kidney disease, which remains to be clarified to date, was also reviewed in these patients. Moreover, because clinical decisions are often based on the values at one point of time, rather than integrated values, the analysis of baseline HbA~1c~ may be easier to interpret in the real world.

5. Conclusions {#sec5}
==============

The progression of renal complications was analyzed according to baseline or dynamic HbA~1c~ for a decade. Although careful interpretation is needed, a less stringent glycemic target is acceptable to prevent renal and other complications. Our findings will be valuable for establishing optimal glycemic targets, particularly in elderly patients with a long duration of diabetes and comorbidities.
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. Figure S1-3 in the Supplementary Material for comprehensive image analysis (changes in baseline glycated hemoglobin, Kaplan-Meier curves for dynamic glycated hemoglobin). Table S1-4 in the Supplementary Material for a statistical complement for dynamic HbA1c or propensity score-weighted analysis.

###### 

Click here for additional data file.

![Development of chronic kidney disease (CKD) in the CKD-naïve group and CKD progression in the preexisting CKD group after 10 years. Abbreviations: CKD: chronic kidney disease; ESRD: end-stage renal disease; eGFR: estimated glomerular filtration rate.](JDR2020-9806790.001){#fig1}

![Kaplan-Meier curves for the development or progression of chronic kidney disease according to baseline glycated hemoglobin. Abbreviations: HbA~1c~: glycated hemoglobin; CKD: chronic kidney disease; No.: number. Kaplan-Meier curves stratified by baseline HbA~1c~ into six groups. Renal outcome was defined as a composite event of the first CKD development in the CKD-naïve group (*n* = 2357) and CKD progression in the preexisting CKD group (*n* = 412).](JDR2020-9806790.002){#fig2}

![Kaplan-Meier curves for the development of end-stage renal disease according to baseline glycated hemoglobin. Abbreviations: HbA~1c~: glycated hemoglobin; ESRD: end-stage renal disease; No.: number. Kaplan-Meier curves stratified by baseline HbA~1c~ into six groups. Renal outcome was defined as the first ESRD development in all subjects including CKD naïve (*n* = 2357), normal GFR with albuminuria (*n* = 330), and preexisting CKD (*n* = 412).](JDR2020-9806790.003){#fig3}

###### 

Baseline patient characteristics according to the glycosylated hemoglobin categories.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                      Baseline HbA~1c~                                                                                                               
  --------------------------------------------------- ------------------ ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ---------
  Age (years)                                         64.67 ± 6.60       65.10 ± 6.92      65.16 ± 6.22      65.25 ± 6.34      64.48 ± 6.88      64.93 ± 5.91      63.29 ± 6.77      \<0.001

  Sex, male *n* (%)                                   2649 (85.48)       631 (91.85)       502 (85.23)       429 (84.78)       313 (84.82)       250 (83.33)       524 (80.86)       \<0.001

  Body mass index (kg/m^2^)                           25.04 ± 3.20       24.78 ± 3.13      24.97 ± 3.28      25.26 ± 2.94      25.02 ± 3.12      25.27 ± 3.72      25.07 ± 3.19      0.176

  HbA~1c~ (mmol/mol)                                  58.68 ± 16.07      41.74 ± 3.94      49.72 ± 1.53      55.07 ± 1.53      60.65 ± 1.53      66.00 ± 1.53      83.27 ± 13.77     \<0.001

  HbA~1c~ (%)                                         7.52 ± 1.47        5.97 ± 0.36       6.70 ± 0.14       7.19 ± 0.14       7.70 ± 0.14       8.19 ± 0.14       9.77 ± 1.26       \<0.001

  SBP (mmHg)                                          129.11 ± 16.93     128.52 ± 17.50    128.95 ± 16.40    130.00 ± 17.10    127.66 ± 15.36    130.79 ± 17.19    129.23 ± 17.35    0.449

  DBP (mmHg)                                          74.14 ± 10.15      74.25 ± 10.12     73.71 ± 9.34      74.25 ± 10.32     72.97 ± 10.08     74.02 ± 10.28     74.96 ± 10.60     0.268

  HDL cholesterol (mmol/L)\                           1.18 ± 0.34        1.22 ± 0.34\      1.19 ± 0.36\      1.19 ± 0.35\      1.16 ± 0.35\      1.19 ± 0.32\      1.13 ± 0.31\      \<0.001
  T~a~:                                                                  a                 a                 ab                ab                ab                b                 

  LDL cholesterol (mmol/L)                            2.61 ± 0.76        2.56 ± 0.76       2.63 ± 0.74       2.57 ± 0.76       2.67 ± 0.68       2.59 ± 0.78       2.67 ± 0.80       0.016

  Triglyceride (mmol/L)\                              4.17 ± 3.30        4.00 ± 3.16\      4.04 ± 2.92\      3.92 ± 2.35\      4.19 ± 2.54\      4.34 ± 3.44\      4.56 ± 4.45\      0.001
  T~a~:                                                                  b                 ab                b                 ab                ab                a                 

  Creatinine (*μ*mol/L)\                              87.52 ± 23.87      88.40 ± 22.10\    90.17 ± 27.40\    87.52 ± 22.98\    85.75 ± 22.10\    85.75 ± 21.22\    84.86 ± 23.87\    0.001
  T~a~:                                                                  ab                a                 ab                ab                ab                b                 

  Uric acid (*μ*mol/L)\                               312.30 ± 86.25     324.19 ± 87.44\   317.65 ± 91.01\   311.11 ± 82.68\   308.73 ± 81.49\   300.40 ± 81.49\   302.18 ± 86.85\   \<0.001
  T~a~:                                                                  a                 ab                ab                ab                b                 b                 

  Albuminuria, *n* (%)                                                                                                                                                               \<0.001

   Normal to mildly increased                         2634 (85.00)       614 (89.37)       509 (86.42)       445 (87.94)       312 (84.55)       250 (83.33)       504 (77.78)       

   Moderately increased                               411 (13.26)        68 (9.90)         71 (12.05)        58 (11.46)        52 (14.09)        44 (14.67)        118 (18.21)       

   Severely increased                                 54 (1.74)          5 (0.73)          9 (1.53)          3 (0.59)          5 (1.36)          6 (2.00)          26 (4.01)         

  Stage of CKD, *n* (%)                                                                                                                                                              0.633

   Stage 1--2 (eGFR ≥ 60 mL/min/1.73 m^2^)            2687 (86.71)       595 (86.61)       495 (84.04)       446 (88.14)       326 (88.35)       260 (86.67)       565 (87.19)       

   Stage 3 (eGFR 30--60 mL/min/1.73 m^2^)             400 (12.90)        90 (13.10)        90 (15.28)        58 (11.46)        41 (11.11)        40 (13.33)        81 (12.50)        

   Stage 4 (eGFR 15--30 mL/min/1.73 m^2^)             12 (0.39)          2 (0.29)          4 (0.68)          2 (0.40)          2 (0.54)          0 (0.0)           2 (0.31)          

  Comorbidities                                                                                                                                                                      

   Hypertension, *n* (%)                              2593 (83.67)       573 (83.41)       486 (82.51)       425 (83.99)       298 (80.76)       247 (82.33)       564 (87.04)       0.121

   Hypercholesterolemia, *n* (%)                      2474 (79.83)       532 (77.44)       475 (80.65)       390 (77.08)       299 (81.03)       244 (81.33)       534 (82.41)       0.131

   Coronary heart disease, *n* (%)                    1509 (48.69)       349 (50.80)       287 (48.73)       237 (46.84)       167 (45.26)       138 (46.00)       331 (51.08)       0.305

   Congestive heart failure, *n* (%)                  380 (12.26)        92 (13.39)        67 (11.38)        53 (10.47)        39 (10.57)        43 (14.33)        86 (13.27)        0.353

   Cerebrovascular disease, *n* (%)                   697 (22.49)        171 (24.89)       128 (21.73)       121 (23.91)       75 (20.33)        62 (20.67)        140 (21.60)       0.427

  Medication                                                                                                                                                                         

   Statin, *n* (%)                                    1576 (50.86)       329 (47.89)       303 (51.44)       251 (49.60)       202 (54.74)       158 (52.67)       333 (51.39)       0.356

  Antihypertensive                                                                                                                                                                   

   ACE inhibitor/ARB, *n* (%)                         1826 (58.92)       398 (57.93)       346 (58.74)       297 (58.70)       206 (55.83)       181 (60.33)       398 (61.42)       0.597

   Beta blocker, *n* (%)                              668 (21.56)        157 (22.85)       145 (24.62)       98 (19.37)        77 (20.87)        61 (20.33)        130 (20.06)       0.252

   Calcium channel blocker, *n* (%)                   986 (31.82)        259 (37.70)       192 (32.60)       168 (33.20)       103 (27.91)       90 (30.00)        174 (26.85)       0.001

   Diuretics, *n* (%)                                 976 (31.49)        232 (33.77)       187 (31.75)       151 (29.84)       115 (31.17)       86 (28.67)        205 (31.64)       0.632

  Glucose-lowering drugs                                                                                                                                                             

   Insulin, *n* (%)                                   401 (12.94)        29 (4.22)         51 (8.66)         60 (11.86)        41 (11.11)        55 (18.33)        165 (25.46)       \<0.001

   Metformin, *n* (%)                                 2265 (73.09)       486 (70.74)       402 (68.25)       360 (71.15)       284 (76.96)       222 (74.00)       511 (78.86)       \<0.001

   Sulfonylurea, *n* (%)                              2224 (71.77)       484 (70.45)       392 (66.55)       382 (75.49)       293 (79.40)       226 (75.33)       447 (68.98)       \<0.001

   Alpha-glucosidase inhibitor (voglibose), *n* (%)   440 (14.20)        94 (13.68)        65 (11.04)        66 (13.04)        67 (18.16)        43 (14.33)        105 (16.20)       0.029

   Thiazolidinedione (actos), *n* (%)                 249 (8.03)         45 (6.55)         47 (7.98)         43 (8.50)         33 (8.94)         25 (8.33)         56 (8.64)         0.705

   Nateglinide (fastic), *n* (%)                      132 (4.26)         34 (4.95)         40 (6.79)         15 (2.96)         18 (4.88)         9 (3.00)          16 (2.47)         0.002
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^∗^ *p* value: categorical data were analyzed using Fisher\'s test or the Chi-square test; continuous data were analyzed using ANOVA; if *p* \< 0.05 in ANOVA, post hoc analysis was performed using Tukey\'s test. T~a~: the same letters indicate nonspecific difference between groups based on Tukey\'s test. Abbreviations: HbA~1c~: glycated hemoglobin; eGFR: estimated glomerular filtration rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; CKD: chronic kidney disease; ACE: angiotensin-converting enzyme; LDL: low-density lipoprotein; HDL: high-density lipoprotein.

###### 

Cox models of baseline glycated hemoglobin for the risk of renal and other microvascular complications.

  Risk factors                                   CKD development & progression   ESRD development          Retinopathy development   Neuropathy development   Diabetic foot development
  ---------------------------------------------- ------------------------------- ------------------------- ------------------------- ------------------------ ---------------------------
  Simple Cox regression                                                                                                                                       
   HbA~1c~, per 1% (11 mmol/mol)                 1.19 (1.14--1.24)^∗^            1.33 (1.16--1.52)^∗^                                                         
    Time \< 1800 days                                                                                      1.00 (0.94--1.06)         1.19 (1.11--1.27)^∗^     1.19 (0.91--1.55)
    Time ≥ 1800 days                                                                                       1.22 (1.15--1.29)^∗^      1.08 (0.97--1.19)        1.24 (1.09--1.40)^∗^
   Age, per 2 years                              1.09 (1.07--1.12)^∗^            0.95 (0.88--1.03)         0.98 (0.96--1)            0.99 (0.97--1.02)        0.99 (0.93--1.06)
   Sex, female vs. male                                                          1.44 (0.57--3.63)         1.26 (1.02--1.57)^†^      1.24 (0.95--1.62)        3.01 (1.10--8.23^)†^
    Time \< 900 days                             1.30 (0.93--1.82)                                                                                            
    Time ≥ 900 days                              0.68 (0.55--0.83)^∗^                                                                                         
   BMI, per 2 kg/m^2^                            0.99 (0.94--1.04)               1.02 (0.86--1.21)         1.02 (0.97--1.08)         0.95 (0.89--1.01)        0.94 (0.82--1.08)
   SBP, per 10 mmHg                              1.05 (1.00--1.1)^†^             1.21 (1.04--1.41)^†^                                0.96 (0.90--1.02)        0.99 (0.88--1.11)
    Time \< 1800 days                                                                                      0.92 (0.86--0.98)^†^                               
    Time ≥ 1800 days                                                                                       1.04 (0.97--1.11)                                  
   DBP, per 10 mmHg                              1.00 (0.93--1.08)                                         1.01 (0.93--1.09)         0.95 (0.86--1.05)        1.15 (0.94--1.4)
    Time \< 3000 days                                                            1.39 (0.99--1.92)                                                            
    Time ≥ 3000 days                                                             0.70 (0.45--1.08)                                                            
   LDL cholesterol, per 0.13 mmol/L              0.99 (0.98--1)                  0.93 (0.89--0.98)^∗^      0.99 (0.98--1)            1.00 (0.98--1.01)        0.98 (0.94--1.01)
   HDL cholesterol, per 0.13 mmol/L                                              0.86 (0.75--0.98)^†^      1.00 (0.97--1.02)         0.97 (0.93--1)           0.79 (0.71--0.88)^∗^
    Time \< 2400 days                            0.90 (0.86--0.93)^∗^                                                                                         
    Time ≥ 2400 days                             0.97 (0.91--1.03)                                                                                            
   Triglyceride, per 0.52 mmol/L                 1.01 (1.00--1.02)^†^            1.02 (0.99--1.04)         1.00 (0.99--1.01)         1.00 (0.98--1.02)        1.02 (1.00--1.04)
   Uric acid, per 59.48 *μ*mol/L                 1.30 (1.24--1.36)^∗^            1.63 (1.40--1.9)^∗^       1.03 (0.98--1.09)         0.95 (0.89--1.02)        1.33 (1.16--1.53)^∗^
   Statin                                                                        1.48 (0.85--2.58)         1.12 (0.98--1.29)         1.14 (0.95--1.37)        1.19 (0.78--1.82)
    Time \< 2400 days                            1.21 (1.04--1.40)^†^                                                                                         
    Time ≥ 2400 days                             0.78 (0.58--1.06)                                                                                            
   Antihypertensive agent                                                        5.97 (1.86--19.15)^∗^     1.27 (1.08--1.5)^∗^                                1.63 (0.97--2.74)
    Time \< 2400 days                            2.18 (1.78--2.66)^∗^                                                                1.62 (1.25--2.11)^∗^     
    Time ≥ 2400 days                             1.20 (0.86--1.67)                                                                   0.96 (0.66--1.40)        
   Glucose-lowering agent                        1.25 (0.76--2.04)               1.12 (0.16--8.15)         1.07 (0.63--1.81)         2.71 (1.01--7.24)^†^     1.48 (0.21--10.67)
   eGFR                                                                          0.93 (0.92--0.95)^∗^      1.00 (1.00--1.00)         1.00 (0.99--1.00)        
   Time \< 2400 days                             0.97 (0.96--0.97)^∗^                                                                                         
   Time ≥ 2400 days                              0.99 (0.98--1.00)^†^                                                                                         
   Proteinuria, + vs (ref = negative or trace)   3.33 (2.67--4.14)^∗^            21.64 (11.12--42.09)^∗^   1.44 (1.21--1.72)^∗^      1.04 (0.80--1.35)        
    Time \< 3650 days                                                                                                                                         2.20 (1.34--3.60)^∗^
    Time ≥ 3650 days                                                                                                                                          0.00 (0.00--Inf)
  Multiple Cox regression                                                                                                                                     
   HbA~1c~, per 1% (11 mmol/mol)                                                 1.37 (1.17--1.60)^∗^                                                         1.20 (1.06--1.35)^∗^
    Time \< 365 days                             1.08 (0.96--1.22)                                                                                            
    Time ≥ 365 days                              1.21 (1.15--1.28)^∗^                                                                                         
    Time \< 1800 days                                                                                      0.98 (0.91--1.05)         1.18 (1.11--1.26)^∗^     
    Time ≥ 1800 days                                                                                       1.18 (1.11--1.26)^∗^      1.07 (0.97--1.18)        
   Age, per 2 years                              1.06 (1.03--1.09)^∗^                                                                                         
   Sex, female vs. male                                                                                                                                       3.29 (0.79--13.63)
   SBP, per 10 mmHg                              1.04 (0.99--1.10)               1.24 (1.04--1.48)^†^                                                         
    Time \< 1800 days                                                                                      0.91 (0.86--0.97)^∗^                               
    Time ≥ 1800 days                                                                                       1.04 (0.97--1.11)                                  
   LDL cholesterol, per 0.13 mmol/L                                              0.93 (0.88--0.98)^∗^                                                         
   HDL cholesterol, per 0.13 mmol/L              0.94 (0.90--0.98)^∗^                                                                                         0.82 (0.73--0.93)^∗^
   Uric acid, per 59.48 *μ*mol/L                 1.15 (1.08--1.22)^∗^                                                                                         1.23 (1.06--1.44)^∗^
   Antihypertensive agent                        1.29 (1.03--1.63)^†^                                                                                         
    Time \< 1800 days                                                                                      1.38 (1.05--1.81)^†^      1.62 (1.22--2.15)^∗^     
    Time ≥ 1800 days                                                                                       0.90 (0.69--1.18)         1.11 (0.80--1.54)        
   Glucose-lowering agent                                                                                                            2.42 (0.90--6.47)        
   eGFR                                                                          0.94 (0.93--0.96)^∗^                                                         
    Time \< 365 days                             0.97 (0.96--0.98)^∗^                                                                                         
    Time ≥ 365 days                              0.99 (0.98--0.99)^∗^                                                                                         
  Proteinuria, + vs (ref = negative or trace)                                    19.61 (7.54--51.03)^∗^    1.31 (1.08--1.58)^∗^                               

A composite analysis of CKD development and progression was performed in CKD naïve and preexisting CKD groups (*n* = 2769). Analysis for the development of ESRD was performed in all subjects (*n* = 3099). Data are presented as hazard ratio (95% confidential interval). ^∗^*p* \< 0.01, ^†^*p* \< 0.05. Abbreviations: HbA~1c~: glycated hemoglobin; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; LDL: low-density lipoprotein; HDL: high-density lipoprotein; eGFR: estimated glomerular filtration rate.

###### 

Cox models for the risk of renal and other microvascular complications according to the baseline glycated hemoglobin level.

  Outcome                               Model         Baseline HbA~1c~                                                                                        
  ------------------------------------- ------------- ------------------ ------------------ --------------------- --------------------- --------------------- ----------------------
  CKD development or progression        HR (95% CI)   1                  1.29 (0.96-1.72)   1.17 (0.86-1.59)      1.07 (0.76-1.49)      1.42 (1.00-2.01)      1.98 (1.52-2.57)^∗^
   Development of CKD                                 1                  1.21 (0.86-1.70)   1.08 (0.76-1.54)      1.10 (0.74-1.63)      1.33 (0.88-2.02)      1.86 (1.38-2.52)^∗^
   Progression of CKD                                 1                  1.57 (0.90-2.72)   1.36 (0.72-2.59)      1.12 (0.58-2.14)      1.66 (0.85-3.22)      2.18 (1.27-3.75)^∗^
  ESRD development                                    1                  2.76 (0.80-9.55)   1.92 (0.53-6.89)      1.86 (0.48-7.11)      1.27 (0.23-7.14)      4.52 (1.44-14.13)^∗^
  *Other microvascular complications*                                                                                                                         
  Development of retinopathy                                                                                                                                  
   Time \< 1800 days                                  1                  1.05 (0.73-1.53)   1.05 (0.72-1.55)      0.75 (0.48-1.18)      0.92 (0.57-1.47)      1.02 (0.72-1.44)
   Time ≥ 1800 days                                   1                  1.37 (0.80-2.33)   1.58 (0.93-2.67)      2.31 (1.39-3.86)^∗^   3.34 (2.01-5.56)^∗^   2.83 (1.81-4.42)^∗^
  Neuropathy                                                                                                                                                  
   Time \< 660 days                                   1                  1.26 (0.61-2.58)   0.79 (0.34-1.83)      1.01 (0.42-2.40)      1.18 (0.47-2.92)      2.09 (1.12-3.92)^†^
   660 ≤ time \< 3300 days                            1                  1.14 (0.69-1.88)   0.91 (0.53-1.56)      2.15 (1.33-3.50)^∗^   1.84 (1.07-3.17)^†^   1.94 (1.25-3.00)^∗^
   Time ≥ 3300 days                                   1                  0.40 (0.11-1.47)   0.88 (0.27-2.84)      0.52 (0.06-4.29)      1.45 (0.36-5.73)      0.47 (0.14-1.58)
  Diabetic foot                                       1                  0.40 (0.14-1.11)   0.31 (0.10-0.98)^†^   1.25 (0.57-2.75)      0.41 (0.12-1.48)      1.35 (0.69-2.65)

A composite analysis of CKD development and progression was performed in CKD-naïve and preexisting CKD groups (*n* = 2769). Analysis for the development of ESRD was performed in all subjects (*n* = 3099). Data are shown as HR (95% confidence interval). ^∗^*p* \< 0.01, ^†^*p* \< 0.05, adjusted for age, sex, body mass index, systolic blood pressure, high-density lipoprotein cholesterol, antihypertensive, and glucose-lowering agents. Abbreviations: CKD: chronic kidney disease; ESRD: end-stage renal disease; HR: hazard ratio; CI: confidence interval.
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